Gottlieb's FDA Lights A Fire Under Medtech Policy Activity But Reimbursement Challenges Remain
Executive Summary
When it comes to the US regulatory and policy environment in 2017, Donald Trump is the first name one must mention. But Trump's unexpected and unconventional presidency is not necessarily the core driving force behind many significant policy developments of most importance to medtech firms in the past year.